Fig. 4.

EGFR and ERK1/2 phosphorylation following treatment of SCC61 cells with test compounds. a Averaged quantification of Western blots analyzing Y¹⁰⁶⁸- or Y¹¹⁷³-phosphorylated EGFR following 1 h pre-treatment with compounds, vehicle, cetuximab, or erlotinib, followed by 45 min treatment with vehicle or EGF +/− EGF. Values shown are normalized to total EGFR. b Averaged quantification of Western blots analyzing T²⁰²/Y²⁰⁴-phosphorylated ERK1/2 following 1 h pre-treatment with compounds, vehicle, cetuximab, or erlotinib, followed by 45 min treatment with vehicle or EGF +/− EGF. Values shown are normalized to total ERK1/2. c Representative Western blots for quantified data shown in parts a and b